Jannik N. Andersen joined Tango Therapeutics as vice President, Biology in January 2019. Jannik brings extensive expertise in basic and applied cancer research to his role at Tango overseeing the integration of functional genomics, drug discovery biology and translational and computational biology. Previously, Jannik worked across the translational continuum in big pharma (Novo Nordisk and Merck & Co), in the biotech industry (Xtuit and Xios Pharmaceuticals) and in major university hospitals, with director-level positions at Dana Farber Cancer Institute and MD Anderson Cancer Center, University of Texas.
Jannik has a multidisciplinary background, first graduating as an Erasmus Scholar from Institut Polytechnique de Grenoble, he also earned a Master of Science in chemical engineering (M.Sc.) from the Technical University of Denmark and a doctorate in human biology from the Faculty of Medicine, University of Copenhagen. He completed his PhD thesis at Novo Nordisk and conducted his post‐doctoral studies at Cold Spring Harbor Laboratory, New York, focusing on molecularly targeted therapies.